Longevity Health Holdings, Inc

Longevity Health Holdings, Inc (NASDAQ: XAGE) is dedicated to promoting longevity and healthy aging by leveraging cutting-edge advancements in regenerative bio-aesthetics. The company offers two specialized cosmetic product lines—Carmell Secretomeand and Elevai Exosomes—designed to enhance skin and hair health. These products are specifically formulated to meet the high-performance standards of professional care providers and meet the expectations of selective retail consumers.

Business Updates

• Strategic Merger Agreement with 20/20 BioLabs: Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company dedicated to advancing human longevity and healthy aging through innovative regenerative bio-aesthetic, diagnostic, and nutritional products, announced it has entered into a merger agreement with 20/20 BioLabs. Executed on April 11, 2025, the agreement outlines that 20/20 BioLabs will continue operating as a wholly owned subsidiary of Longevity Health Holdings following the merger’s completion, pending customary closing conditions. Additionally, Longevity Health has filed an S-4 prospectus with the SEC as of May 8, 2025, in connection with the transaction.
• Q1 Sales Growth and Recent Stock Adjustment: For the first quarter, Longevity Health Holdings reported unaudited pro forma sales of approximately USD 663,000, reflecting an 8% increase compared to the same period last year. Similarly, 20/20 BioLabs posted sales of approximately USD 562,000, marking a 15% year-over-year growth. On May 12, 2025, Longevity Health completed a 1-for-30 reverse stock split of its common stock, with trading of the split-adjusted shares commencing on May 14, 2025.
• Upcoming Product Launches and Collaborative Initiatives: Longevity Health plans to launch a medicated cleanser designed for use in physicians’ offices and MedSpas during the second quarter. This product will also be marketed to 20/20 BioLabs’ predominantly firefighter customer base. Meanwhile, 20/20 BioLabs is preparing to introduce a new lab test that measures inflammatory biomarkers—key factors in premature aging and various skin and health conditions. This test will be marketed to Longevity Health’s physician and MedSpa customers. Furthermore, 20/20 has initiated a pilot program with Giant Food in nine stores across Maryland and Virginia to offer their OneTestTM multi-cancer test, with potential expansion to include a test for biomarkers related to pro-inflammatory foods.
• Future Financing and Company Overview: Longevity Health Holdings is currently evaluating financing options and expects to announce a primary investment in the second quarter of 2025. As a leader in early detection and chronic disease risk management, 20/20 BioLabs develops innovative laboratory tests, including a multi-cancer early detection blood test available for at-home or retail access. The company’s upcoming inflammatory biomarker test targets chronic inflammation, a major contributor to many leading causes of death in the U.S. as well as various skin disorders.

Technical Observation (on the daily chart):

The chart for Longevity Health Holdings shows a persistent downtrend over the past year, with the stock falling from over USD 80 to around USD 3.06. It remains below both the 21-day and 50-day moving averages, indicating continued bearish momentum. The RSI is weak at 37.38, suggesting limited buying interest, and trading volume is low aside from a few brief spikes. With no signs of a trend reversal, the stock appears to be under sustained selling pressure, and further downside is possible unless it breaks above key resistance levels with strong volume.

Longevity Health Holdings (Nasdaq: XAGE) recently announced a merger agreement with 20/20 BioLabs, aiming to expand its footprint in regenerative bio-aesthetics and diagnostics, with 20/20 continuing as a subsidiary post-merger. Both companies reported modest first-quarter sales growth, with XAGE up 8% and 20/20 up 15%, while XAGE completed a 1-for-30 reverse stock split to enhance its market profile. Looking ahead, both firms plan new product launches targeting physicians, MedSpas, and specialized customer groups, alongside a pilot program with Giant Food for advanced cancer and inflammation testing. Despite these positive developments, the company is also exploring new financing options, reflecting a balanced approach to growth amid ongoing market challenges. 

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to Longevity Health Holdings, Inc (NASDAQ: XAGE) at the closing market price of USD 3.06 as of May 21,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 21,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.